Captrust Financial Advisors Buys 340 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Captrust Financial Advisors grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 20.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,988 shares of the company’s stock after purchasing an additional 340 shares during the period. Captrust Financial Advisors’ holdings in TransMedics Group were worth $312,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in TMDX. International Assets Investment Management LLC purchased a new position in TransMedics Group during the 2nd quarter valued at approximately $47,000. USA Financial Formulas purchased a new position in shares of TransMedics Group in the third quarter valued at $55,000. Signaturefd LLC increased its position in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Farther Finance Advisors LLC increased its position in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Finally, Rakuten Securities Inc. purchased a new stake in TransMedics Group during the third quarter valued at $126,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. dropped their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Finally, Canaccord Genuity Group decreased their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.80.

Insider Buying and Selling

In other news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,042 shares of company stock valued at $3,563,985 over the last quarter. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Stock Down 2.2 %

Shares of TMDX opened at $64.26 on Friday. The firm has a market capitalization of $2.16 billion, a P/E ratio of 68.36 and a beta of 2.06. TransMedics Group, Inc. has a 12-month low of $63.42 and a 12-month high of $177.37. The firm has a fifty day moving average price of $95.77 and a 200-day moving average price of $131.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period last year, the firm earned ($0.12) earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.